Industrial-academic Cooperation Trend: A Good Way to Promote Biological Studies
In the past few years, research funds for bio-pharmaceutical industry have shown a downward trend. In order to get out of this predicament, pharmaceutical companies begin to seek opportunity to work with academic institutions to develop new drugs. Especially with the approaching of expiration of drug patents, many companies are trying to accelerate the drug development process in order to occupy a favorable position in the industry reshuffle. Meanwhile, such cooperation is also a good thing for research institutions, which promote the integration and healthy competition between research institutions and biological industry.
For example, recently the pharmaceutical giant Pfizer established strategic partnership with Sanford-Burnham Medical Research Institute in the field of obesity and diabetes. Rick Vega from the institute said that due to the impact of economic development, the fund for academics decreased, while cooperation with enterprises can increase the diversity of funding sources.
Regarding the phenomenon, some experts give positive evaluation and hope the model to be promoted in other agencies in the future.
Creative BioMart is just one of such institutions that provide quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymesto the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.